Advancements in Autologous Stem Cell Transplantation for Parkinson's Disease

Overview

Journal Curr Stem Cell Res Ther

Publisher Bentham Science Publishers

Specialties Cell Biology
Pharmacology

Date 2023 Sep 11

PMID 37691194

Authors

Jia-Xin Shi

Ke-Zhong Zhang

Affiliations

Soon will be listed here.

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disease marked by comparatively focal dopaminergic neuron degeneration in the substantia nigra of the midbrain and dopamine loss in the striatum, which causes motor and non-motor symptoms. Currently, pharmacological therapy and deep brain stimulation (DBS) are the primary treatment modalities for PD in clinical practice. While these approaches offer temporary symptom control, they do not address the underlying neurodegenerative process, and complications often arise. Stem cell replacement therapy is anticipated to prevent further progression of the disease due to its regenerative capacity, and considering the cost of immunosuppression and the potential immune dysfunctions, autologous stem cell transplantation holds promise as a significant method against allogeneic one to treat Parkinson's disease. In this review, the safety concerns surrounding tumorigenicity and complications associated with transplantation are discussed, along with methods utilized to evaluate the efficacy of such procedures. Subsequently, we summarize the preclinical and clinical studies involving autologous stem cell transplantation for PD, and finally talk about the benefits of autologous stem cell transplantation against allogeneic transplants.

References

McGregor M, Nelson A . Circuit Mechanisms of Parkinson's Disease. Neuron. 2019; 101(6):1042-1056. DOI: 10.1016/j.neuron.2019.03.004. View

Antonini A, Moro E, Godeiro C, Reichmann H . Medical and surgical management of advanced Parkinson's disease. Mov Disord. 2018; 33(6):900-908. DOI: 10.1002/mds.27340. View

Cury R, Pavese N, Aziz T, Krauss J, Moro E . Gaps and roadmap of novel neuromodulation targets for treatment of gait in Parkinson's disease. NPJ Parkinsons Dis. 2022; 8(1):8. PMC: 8752758. DOI: 10.1038/s41531-021-00276-6. View

Hidding U, Gulberti A, Pflug C, Choe C, Horn A, Prilop L . Modulation of specific components of sleep disturbances by simultaneous subthalamic and nigral stimulation in Parkinson's disease. Parkinsonism Relat Disord. 2019; 62:141-147. DOI: 10.1016/j.parkreldis.2018.12.026. View

Tsui A, Isacson O . Functions of the nigrostriatal dopaminergic synapse and the use of neurotransplantation in Parkinson's disease. J Neurol. 2011; 258(8):1393-405. DOI: 10.1007/s00415-011-6061-6. View

Parmar M, Grealish S, Henchcliffe C . The future of stem cell therapies for Parkinson disease. Nat Rev Neurosci. 2020; 21(2):103-115. DOI: 10.1038/s41583-019-0257-7. View

Osborn T, Hallett P, Schumacher J, Isacson O . Advantages and Recent Developments of Autologous Cell Therapy for Parkinson's Disease Patients. Front Cell Neurosci. 2020; 14:58. PMC: 7147334. DOI: 10.3389/fncel.2020.00058. View

Tao Y, Vermilyea S, Zammit M, Lu J, Olsen M, Metzger J . Autologous transplant therapy alleviates motor and depressive behaviors in parkinsonian monkeys. Nat Med. 2021; 27(4):632-639. PMC: 8198752. DOI: 10.1038/s41591-021-01257-1. View

Piao J, Zabierowski S, Dubose B, Hill E, Navare M, Claros N . Preclinical Efficacy and Safety of a Human Embryonic Stem Cell-Derived Midbrain Dopamine Progenitor Product, MSK-DA01. Cell Stem Cell. 2021; 28(2):217-229.e7. PMC: 7903922. DOI: 10.1016/j.stem.2021.01.004. View

10.

Morizane A, Takahashi J . Evading the Immune System: Immune Modulation and Immune Matching in Cell Replacement Therapies for Parkinson's Disease. J Parkinsons Dis. 2021; 11(s2):S167-S172. PMC: 8543266. DOI: 10.3233/JPD-212608. View

11.

Yousefi N, Abdollahii S, Jadidi Kouhbanani M, Hassanzadeh A . Induced pluripotent stem cells (iPSCs) as game-changing tools in the treatment of neurodegenerative disease: Mirage or reality?. J Cell Physiol. 2020; 235(12):9166-9184. DOI: 10.1002/jcp.29800. View

12.

Fan Y, Winanto , Ng S . Replacing what's lost: a new era of stem cell therapy for Parkinson's disease. Transl Neurodegener. 2020; 9:2. PMC: 6945567. DOI: 10.1186/s40035-019-0180-x. View

13.

Shrigley S, Nilsson F, Mattsson B, Fiorenzano A, Mudannayake J, Bruzelius A . Grafts Derived from an α-Synuclein Triplication Patient Mediate Functional Recovery but Develop Disease-Associated Pathology in the 6-OHDA Model of Parkinson's Disease. J Parkinsons Dis. 2020; 11(2):515-528. PMC: 8150478. DOI: 10.3233/JPD-202366. View

14.

Schweitzer J, Song B, Herrington T, Park T, Lee N, Ko S . Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson's Disease. N Engl J Med. 2020; 382(20):1926-1932. PMC: 7288982. DOI: 10.1056/NEJMoa1915872. View

15.

Lanza R, Russell D, Nagy A . Engineering universal cells that evade immune detection. Nat Rev Immunol. 2019; 19(12):723-733. DOI: 10.1038/s41577-019-0200-1. View

16.

Giehrl-Schwab J, Giesert F, Rauser B, Lao C, Hembach S, Lefort S . Parkinson's disease motor symptoms rescue by CRISPRa-reprogramming astrocytes into GABAergic neurons. EMBO Mol Med. 2022; 14(5):e14797. PMC: 9081909. DOI: 10.15252/emmm.202114797. View

17.

Takahashi K, Yamanaka S . Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126(4):663-76. DOI: 10.1016/j.cell.2006.07.024. View

18.

Wang H, Yang Y, Liu J, Qian L . Direct cell reprogramming: approaches, mechanisms and progress. Nat Rev Mol Cell Biol. 2021; 22(6):410-424. PMC: 8161510. DOI: 10.1038/s41580-021-00335-z. View

19.

Zheng W, Chen Z . Generation of Induced Neural Stem Cells from Peripheral Mononuclear Cells and Differentiation Toward Dopaminergic Neuron Precursors for Transplantation Studies. J Vis Exp. 2019; (149). DOI: 10.3791/59690. View

20.

Gugliandolo A, Bramanti P, Mazzon E . Mesenchymal stem cell therapy in Parkinson's disease animal models. Curr Res Transl Med. 2017; 65(2):51-60. DOI: 10.1016/j.retram.2016.10.007. View